References
- 1. RODRIGO L., BETETA-GORRITI V., ALVAREZ N., GÓMEZ DE CASTRO C., DE DIOS A., PALACIOS L., et al. Cutaneous and mucosal manifestations associated with celiac disease. Nutrients. 2018;10(7):800.
- 2. CAIO G., VOLTA U., SAPONE A., LEFFLER DA., DE GIORGIO R., CATASSI C., et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17(1):142.
- 3. ASRI N., ROSTAMI-NEJAD M. The Facts of Celiac Disease; A Comprehensive Review. Int J Celiac Dis. 2022;7(2):48–52.
- 4. ROSTAMI-NEJAD M., ROMANOS J., ROSTAMI K., GANJI A., EHSANI-ARDAKANI MJ., BAKHSHIPOUR AR., et al. Allele and haplotype frequencies for HLA-DQ in Iranian celiac disease patients. World J Gastroenterol. 2014;20(20):6302–8.
- 5. TYE-DIN JA., GALIPEAU HJ., AGARDH D. Celiac disease: a review of current concepts in pathogenesis, prevention, and novel therapies. Front Pediatr. 2018;6:350.
- 6. ROSTAMI-NEJAD M., EMAMI MH., ZALI M., MALEKZADEH R., ROSTAMI K. Epidemiology of Celiac Disease in Iran: A Review. Middle East J Dig Dis. 2011;3(1):5–12.
- 7. ROSTAMI-NEJAD M. Crucial role of innate immune system in the pathogenesis of celiac disease. Arvand J Health Med Sci 2016;1(3):125–34.
- 8. MAZZARELLA G. Effector and suppressor T cells in celiac disease. World J Gastroenterol. 2015;21(24):7349–56.
- 9. CICERONE C., NENNA R., PONTONE S. Th17, intestinal microbiota and the abnormal immune response in the pathogenesis of celiac disease. Gastroenterol Hepatol Bed Bench. 2015;8(2):117–22.
- 10. LING H., FABBRI M., CALIN GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65.
- 11. KEFAS B., COMEAU L., FLOYD DH., SELEVERSTOV O., GODLEWSKI J., SCHMITTGEN T., et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 2009;29(48):15161–8.
- 12. JADIDESLAM G., ANSARIN K., SAKHINIA E., ALIPOUR S., POUREMAMALI F., KHABAZI A. The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target. J Cell Physiol. 2018;233(12):9209–9222
- 13. GARRETT-SINHA LA. Review of Ets1 structure, function, and roles in immunity. Cell Mol Life Sci. 2013;70(18):3375–90.
- 14. JADIDESLAM G., ANSARIN K, SAKHINIA E., ALIPOUR S., POUREMAMALI F., KHABBAZI A. The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target. J Cell Physiol. 2018;233(12):9209–22.
- 15. KUMAR V., WIJMENGA C., WITHOFF S. From genome-wide association studies to disease mechanisms: celiac disease as a model for autoimmune diseases. Semin Immunopathol. 2012;34(4):567–80.
- 16. SHAN S., DANG J., LI J., YANG Z., ZHAO H., XIN Q., et al. ETS1 variants confer susceptibility to ankylosing spondylitis in Han Chinese. Arthritis Res Ther. 2014;16(2): R87.
- 17. LA SCALEIA R., BARBA M., DI NARDO G., BONAMICO M., OLIVA S., NENNA R., et al. Size and dynamics of mucosal and peripheral IL-17A+ T-cell pools in pediatric age, and their disturbance in celiac disease. Mucosal immunol. 2012;5(5):513–23.
- 18. ZHAO N., ZOU H., QIN J., FAN C., LIU Y., WANG S., et al. MicroRNA-326 contributes to autoimmune thyroiditis by targeting the Ets-1 protein. Endocrine. 2018;59(1):120–9.
- 19. DU C., LIU C., KANG J., ZHAO G., YE Z., HUANG S., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12):1252–9.
- 20. FAGHIH M., ROSTAMI-NEJAD M., AMANI D., SADEGHI A., POURHOSEINGHOLI MA., MASOTTI A., et al. Analysis of IL17A and IL21 expression in the small intestine of celiac disease patients and correlation with circulating thioredoxin level. Genet Test Mol Biomark. 2018;22(9): 518–25.
- 21. FASANO A., CATASSI C. Celiac disease. N Engl J Med. 2012;367(25): 2419–26.
- 22. HOU Y., FENG Q., XU M., LI GS., LIU XN., SHENG Z., et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. Blood. 2016;127(12):1587–97.
- 23. DU C., LIU C., KANG J., ZHAO G., YE Z., HUANG S., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12):1252–9.
- 24. SUN DL., CEN YY., LI SM., LI WM., LU QP., XU PY. Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: a meta-analysis. Sci Rep. 2016;6:34371.
- 25. FRISULLO G., NOCITI V., IORIO R., PATANELLA AK., PLANTONE D., BIANCO A., et al. T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clin Exp Immunol. 2009;158(1):106–14.
- 26. KHALKHAL E., NOBAKHT F., HAIDARI MH., RAZAGHI Z., GHASEMZAD M., SHEIKHAN M., et al. Evaluation common genes expression in the intestine and peripheral blood monocytes (PBMC) associated with celiac disease. Gastroenterol Hepatol Bed Bench. 2020;13(Suppl.1):S60–S67.